Boryung Pharmaceutical Co Ltd is a pharmaceutical company. It manufactures and distributes pharmaceutical products including cardiovascular, anticancer and gastrointestinal drugs. The company offers products such as Kanarb, Gelfos, Maxpim injection, mayact tablet, among others. The company's product portfolio focusses on the chronical diseases including hypertension, dyslipidemia, diabetes, CNS disorders, and cancers. It also offers products including Dukarb Plus, Zepzelca, Finjuve Spray, among others. The company also provides marketed API along with anti-cancer injection facilities. The company reported revenues of $860 million for the fiscal year ended December 2023 (FY2023), an increase of 13% over FY2022.

Biopharmaceuticals: Boryung has a strong focus on biopharmaceuticals, particularly in the development of biologics and biosimilars. This involves advanced technologies in protein engineering, cell culture, and purification. Formulation Development: The company excels in formulation development, creating innovative dosage forms to enhance drug delivery and patient compliance. This includes technologies like controlled-release, targeted delivery, and nanoparticle-based formulations. Drug Repurposing: Boryung has shown a keen interest in drug repurposing, which involves identifying new uses for existing drugs. This approach can accelerate drug development and reduce costs.

Private

Pharma, Investor, CDMO, Bio